Cargando…

Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.

Rapid and simple enzyme immunoassays (EIAs) were recently developed to measure 2-hydroxyestrone and 16alpha-hydroxyestrone in unextracted urine. The balance between these competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk. Before testing these assays in epidemiolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, R G, Rossi, S C, Fears, T R, Bradlow, H L, Adlercreutz, H, Sepkovic, D, Kiuru, P, Wahala, K, Vaught, J B, Donaldson, J L, Falk, R T, Fillmore, C M, Siiteri, P K, Hoover, R N, Gail, M H
Formato: Texto
Lenguaje:English
Publicado: 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1469903/
https://www.ncbi.nlm.nih.gov/pubmed/9168003
_version_ 1782127709080518656
author Ziegler, R G
Rossi, S C
Fears, T R
Bradlow, H L
Adlercreutz, H
Sepkovic, D
Kiuru, P
Wahala, K
Vaught, J B
Donaldson, J L
Falk, R T
Fillmore, C M
Siiteri, P K
Hoover, R N
Gail, M H
author_facet Ziegler, R G
Rossi, S C
Fears, T R
Bradlow, H L
Adlercreutz, H
Sepkovic, D
Kiuru, P
Wahala, K
Vaught, J B
Donaldson, J L
Falk, R T
Fillmore, C M
Siiteri, P K
Hoover, R N
Gail, M H
author_sort Ziegler, R G
collection PubMed
description Rapid and simple enzyme immunoassays (EIAs) were recently developed to measure 2-hydroxyestrone and 16alpha-hydroxyestrone in unextracted urine. The balance between these competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk. Before testing these assays in epidemiologic studies, we evaluated their reproducibility, and validity relative to gas chromatography-mass spectroscopy (GC-MS). Overnight 12-hr urine collections from five midfollicular premenopausal women, five midluteal premenopausal women, and five postmenopausal women were aliquoted and stored at -70 degrees C. Two aliquots from each woman were assayed with the EIAs in a random, blinded order, monthly over 4 months and 1 year later. Reproducibility over 4 months was good for both metabolites in premenopausal women (coefficient of variation = 8-14%) and satisfactory in postmenopausal women (approximately 19%). Reproducibility over 12 months remained good in premenopausal women, but was poor in postmenopausal women, with mean readings increasing 50 to 100%. Wide variation in estrogen metabolite levels enabled a single EIA measurement to characterize individual differences among premenopausal women in midfollicular (intraclass correlation coefficient = 98-99%) and midluteal phase (85-91%). A narrower range in metabolite levels among postmenopausal women reduced discrimination (78-82%). The correlation between EIA and GC-MS measurement was excellent for both metabolites (r>0.9), except for 2-hydroxyestrone in postmenopausal women (r=0.6). Analysis of absolute agreement suggested that both EIAs were less sensitive than GC-MS, and each detected nonspecific background. The low concentration of estrogen metabolites in urine from postmenopausal women may explain the problems with reproducibility and validity in this menstrual group. Accordingly, more sensitive EIAs have been developed and are now being evaluated.
format Text
id pubmed-1469903
institution National Center for Biotechnology Information
language English
publishDate 1997
record_format MEDLINE/PubMed
spelling pubmed-14699032006-06-01 Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Ziegler, R G Rossi, S C Fears, T R Bradlow, H L Adlercreutz, H Sepkovic, D Kiuru, P Wahala, K Vaught, J B Donaldson, J L Falk, R T Fillmore, C M Siiteri, P K Hoover, R N Gail, M H Environ Health Perspect Research Article Rapid and simple enzyme immunoassays (EIAs) were recently developed to measure 2-hydroxyestrone and 16alpha-hydroxyestrone in unextracted urine. The balance between these competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk. Before testing these assays in epidemiologic studies, we evaluated their reproducibility, and validity relative to gas chromatography-mass spectroscopy (GC-MS). Overnight 12-hr urine collections from five midfollicular premenopausal women, five midluteal premenopausal women, and five postmenopausal women were aliquoted and stored at -70 degrees C. Two aliquots from each woman were assayed with the EIAs in a random, blinded order, monthly over 4 months and 1 year later. Reproducibility over 4 months was good for both metabolites in premenopausal women (coefficient of variation = 8-14%) and satisfactory in postmenopausal women (approximately 19%). Reproducibility over 12 months remained good in premenopausal women, but was poor in postmenopausal women, with mean readings increasing 50 to 100%. Wide variation in estrogen metabolite levels enabled a single EIA measurement to characterize individual differences among premenopausal women in midfollicular (intraclass correlation coefficient = 98-99%) and midluteal phase (85-91%). A narrower range in metabolite levels among postmenopausal women reduced discrimination (78-82%). The correlation between EIA and GC-MS measurement was excellent for both metabolites (r>0.9), except for 2-hydroxyestrone in postmenopausal women (r=0.6). Analysis of absolute agreement suggested that both EIAs were less sensitive than GC-MS, and each detected nonspecific background. The low concentration of estrogen metabolites in urine from postmenopausal women may explain the problems with reproducibility and validity in this menstrual group. Accordingly, more sensitive EIAs have been developed and are now being evaluated. 1997-04 /pmc/articles/PMC1469903/ /pubmed/9168003 Text en
spellingShingle Research Article
Ziegler, R G
Rossi, S C
Fears, T R
Bradlow, H L
Adlercreutz, H
Sepkovic, D
Kiuru, P
Wahala, K
Vaught, J B
Donaldson, J L
Falk, R T
Fillmore, C M
Siiteri, P K
Hoover, R N
Gail, M H
Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title_full Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title_fullStr Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title_full_unstemmed Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title_short Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
title_sort quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1469903/
https://www.ncbi.nlm.nih.gov/pubmed/9168003
work_keys_str_mv AT zieglerrg quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT rossisc quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT fearstr quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT bradlowhl quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT adlercreutzh quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT sepkovicd quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT kiurup quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT wahalak quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT vaughtjb quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT donaldsonjl quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT falkrt quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT fillmorecm quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT siiteripk quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT hooverrn quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine
AT gailmh quantifyingestrogenmetabolismanevaluationofthereproducibilityandvalidityofenzymeimmunoassaysfor2hydroxyestroneand16alphahydroxyestroneinurine